Recombinant human angiotensin-converting enzyme 2 as a new renin-angiotensin system peptidase for heart failure therapy

Current Heart Failure Reports

Volumn 8, Issue 3, 2011, Pages 176-183

  Oudit, Gavin Y ^a   Penninger, Josef M ^b  

^a MAZANKOWSKI ALBERTA HEART INSTITUTE   (Canada)

^b INSTITUTE OF MOLECULAR BIOTECHNOLOGY   (Austria)

Author keywords

ACE2; Ang 1 7; Ang II; Angiotensin 1 7; Angiotensin converting enzyme 2; Angiotensin II; Chymase; Diastolic dysfunction; Heart failure; Hypertrophy; Myocardial fibrosis; NADPH oxidase; Recombinant human angiotensin converting enzyme 2; RhACE2; Signaling; Therapy

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN CONVERTING ENZYME 2; ANGIOTENSIN II; ANGIOTENSIN[1-7]; APELIN; APELIN RECEPTOR; PEPTIDASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; RENIN;

ARTICLE; ATHEROSCLEROSIS; DIASTOLIC DYSFUNCTION; DRUG EFFICACY; DRUG HALF LIFE; ENZYME ACTIVITY; HEART FAILURE; HEART INFARCTION; HEART MUSCLE FIBROSIS; HUMAN; NONHUMAN; PROTEIN EXPRESSION; SYSTOLIC DYSFUNCTION;

ANGIOTENSIN I; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; DIASTOLE; HEART FAILURE; HUMANS; PEPTIDE FRAGMENTS; PEPTIDYL-DIPEPTIDASE A; RECOMBINANT PROTEINS; RENIN-ANGIOTENSIN SYSTEM; SIGNAL TRANSDUCTION;

EID: 80055049289     PISSN: 15469530     EISSN: 15469549     Source Type: Journal    
DOI: 10.1007/s11897-011-0063-7     Document Type: Article

References (81)

1. Roger VL, Go AS, Lloyd-Jones DM, et al. Executive Summary: Heart Disease and Stroke Statistics-2011 Update: A Report From the American Heart Association. Circulation. 2011;123:459-463.
2. Zaman MA, Oparil S, Calhoun DA. Drugs targeting the reninangiotensin- aldosterone system. Nat Rev Drug Discov. 2002;1:621-636. (Pubitemid 37368827)
3. Tipnis SR, Hooper NM, Hyde R, et al. A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase. J Biol Chem. 2000;275:33238-33243.
4. Donoghue M, Hsieh F, Baronas E, et al. A novel angiotensinconverting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res. 2000;87:E1-E9.
5. Crackower MA, Sarao R, Oudit GY, et al. Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature. 2002;417:822-828. (Pubitemid 34670323)
6. Oudit GY, Kassiri Z, Patel MP, et al. Angiotensin II-mediated oxidative stress and inflammation mediate the age-dependent cardiomyopathy in ACE2 null mice. Cardiovasc Res. 2007;75:29-39. (Pubitemid 46873522)
7. Zhong JC, Basu R, Guo D, et al. Angiotensin converting enzyme 2 suppresses pathological hypertrophy, myocardial fibrosis and cardiac dysfunction. Circulation. 2010;122:717-728.
8. Bodiga S, Zhong JC, Wang W, et al. Enhanced susceptibility to biomechanical stress in ACE2 null mice is prevented by loss of the p47phox NADPH oxidase subunit. Cardiovasc Res 2011; doi:10.1093/cvr/cvr036.
9. Lovren F, Pan Y, Quan A, et al. Angiotensin converting enzyme-2 confers endothelial protection and attenuates atherosclerosis. Am J Physiol Heart Circ Physiol. 2008;295:H1377-H1384.
10. Rentzsch B, Todiras M, Iliescu R, et al. Transgenic angiotensinconverting enzyme 2 overexpression in vessels of SHRSP rats reduces blood pressure and improves endothelial function. Hypertension. 2008;52:967-973.
11. Wysocki J, Ye M, Rodriguez E, et al. Targeting the degradation of angiotensin II with recombinant angiotensin-converting enzyme 2: prevention of angiotensin II-dependent hypertension. Hypertension. 2009;55:90-98.
12. Oudit GY, Herzenberg AM, Kassiri Z, et al. Loss of angiotensinconverting enzyme-2 leads to the late development of angiotensin II-dependent glomerulosclerosis. Am J Pathol. 2006;168:1808-1820. (Pubitemid 43825302)
13. Oudit GY, Liu GC, Zhong J, et al. Human recombinant ACE2 reduces the progression of diabetic nephropathy. Diabetes. 2010;59:529-538.
14. Zhong J, Guo D, Chen CB, et al. Prevention of angiotensin iimediated renal oxidative stress, inflammation, and fibrosis by angiotensin-converting enzyme 2. Hypertension. 2011;57:314-322.
15. Vickers C, Hales P, Kaushik V, et al. Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase. J Biol Chem. 2002;277:14838-14843. (Pubitemid 34952556)
16. Santos RA, Silva AC Simoes e, Maric C, et al. Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc Natl Acad Sci USA. 2003;100:8258-8263. (Pubitemid 36842532)
17. Mercure C, Yogi A, Callera GE, et al. Angiotensin(1-7) blunts hypertensive cardiac remodeling by a direct effect on the heart. Circ Res. 2008;103:1319-1326.
18. Garabelli PJ, Modrall JG, Penninger JM, et al. Distinct roles for angiotensin-converting enzyme 2 and carboxypeptidase A in the processing of angiotensins within the murine heart. Exp Physiol. 2008;93:613-621. (Pubitemid 351595064)
19. Kassiri Z, Zhong J, Guo D, et al. Loss of angiotensin-converting enzyme 2 accelerates maladaptive left ventricular remodeling in response to myocardial infarction. Circ Heart Fail. 2009;2:446-455.
20. Santos RA, Ferreira AJ, Pinheiro SV, et al. Angiotensin-(1-7) and its receptor as a potential targets for new cardiovascular drugs. Expert Opin Investig Drugs. 2005;14:1019-1031. (Pubitemid 41131653)
21. Lee DK, Cheng R, Nguyen T, et al. Characterization of apelin, the ligand for the APJ receptor. J Neurochem. 2000;74:34-41. (Pubitemid 30012752)
22. Pitkin SL, Maguire JJ, Bonner TI, Davenport AP. International union of basic and clinical pharmacology. LXXIV. Apelin receptor nomenclature, distribution, pharmacology, and function. Pharmacol Rev. 2010;62:331-342.
23. Bhatia RS, Tu JV, Lee DS, et al. Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med. 2006;355:260-269. (Pubitemid 44088349)
24. Owan TE, Hodge DO, Herges RM, et al. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med. 2006;355:251-259. (Pubitemid 44079340)
25. Zile MR, Brutsaert DL. New concepts in diastolic dysfunction and diastolic heart failure: Part II: causal mechanisms and treatment. Circulation. 2002;105:1503-1508. (Pubitemid 34263285)
26. Iwata M, Cowling RT, Gurantz D, et al. Angiotensin-(1-7) binds to specific receptors on cardiac fibroblasts to initiate antifibrotic and antitrophic effects. Am J Physiol Heart Circ Physiol. 2005;289:H2356-H2363. (Pubitemid 41698543)
27. Weber KT, Brilla CG. Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system. Circulation. 1991;83:1849-1865.
28. Grobe JL, Der Sarkissian S, Stewart JM, et al. ACE2 overexpression inhibits hypoxia-induced collagen production by cardiac fibroblasts. Clin Sci Lond. 2007;113(8):357-364. (Pubitemid 47572276)
29. Huentelman MJ, Grobe JL, Vazquez J, et al. Protection from angiotensin II-induced cardiac hypertrophy and fibrosis by systemic lentiviral delivery of ACE2 in rats. Exp Physiol. 2005;90:783-790. (Pubitemid 41406067)
30. Gurley SB, Allred A, Le TH, et al. Altered blood pressure responses and normal cardiac phenotype in ACE2-null mice. J Clin Invest. 2006;116(8):2218- 2225. (Pubitemid 44162331)
31. Goulter AB, Goddard MJ, Allen JC, Clark KL. ACE2 gene expression is up-regulated in the human failing heart. BMC Med. 2004;2:19.
32. Ishiyama Y, Gallagher PE, Averill DB, et al. Upregulation of angiotensin-converting enzyme 2 after myocardial infarction by blockade of angiotensin II receptors. Hypertension. 2004;43:970-976. (Pubitemid 38579900)
33. Burrell LM, Risvanis J, Kubota E, et al. Myocardial infarction increases ACE2 expression in rat and humans. Eur Heart J. 2005;26:369-375. (Pubitemid 40283096)
34. Yamamoto K, Ohishi M, Katsuya T, et al. Deletion of angiotensinconverting enzyme 2 accelerates pressure overload-induced cardiac dysfunction by increasing local angiotensin II. Hypertension. 2006;47:718-726. (Pubitemid 43740244)
35. Kassiri Z, Khokha R. Myocardial extra-cellular matrix and its regulation by metalloproteinases and their inhibitors. Thromb Haemost. 2005;93:212-219. (Pubitemid 40253724)
36. Zhao YX, Yin HQ, Yu QT, et al. ACE2 overexpression ameliorates left ventricular remodeling and dysfunction in a rat model of myocardial infarction. Hum Gene Ther. 2010;21:1545-1554.
37. Lieb W, Graf J, Gotz A, et al. Association of angiotensinconverting enzyme 2 (ACE2) gene polymorphisms with parameters of left ventricular hypertrophy in men. Results of the MONICA Augsburg echocardiographic substudy. J Mol Med. 2006;84:88-96. (Pubitemid 43099527)
38. Yang W, Huang W, Su S, et al. Association study of ACE2 (angiotensin I-converting enzyme 2) gene polymorphisms with coronary heart disease and myocardial infarction in a Chinese Han population. Clin Sci Lond. 2006;111:333-340. (Pubitemid 44696255)
39. Keidar S, Strizevsky A, Raz A, Gamliel-Lazarovich A. ACE2 activity is increased in monocyte-derived macrophages from prehypertensive subjects. Nephrol Dial Transplant. 2007;22:597-5601.
40. Zhong J, Yan Z, Liu D, et al. Association of angiotensinconverting enzyme 2 gene A/G polymorphism and elevated blood pressure in Chinese patients with metabolic syndrome. J Lab Clin Med. 2006;147:91-95. (Pubitemid 43189001)
41. Epelman S, Shrestha K, Troughton RW, et al. Soluble angiotensin- converting enzyme 2 in human heart failure: relation with myocardial function and clinical outcomes. J Card Fail. 2009;15:565-571.
42. Wang Y, Moreira Mda C, Heringer-Walther S, et al. Plasma ACE2 activity is an independent prognostic marker in Chagas' disease and equally potent as BNP. J Card Fail. 2010;16:157-163.
43. Carretero OA, Oparil S. Essential hypertension. Part I: definition and etiology. Circulation. 2000;101:329-335. (Pubitemid 30054162)
44. Stoll M, Jacob HJ. Genetic rat models of hypertension: relationship to human hypertension. Curr Hypertens Rep. 2001;3:157-164.
45. Oudit GY, Crackower MA, Backx PH, Penninger JM. The role of ACE2 in cardiovascular physiology. Trends Cardiovasc Med. 2003;13:93-101. (Pubitemid 36411803)
46. Yamazato M, Yamazato Y, Sun C, et al. Overexpression of angiotensin-converting enzyme 2 in the rostral ventrolateral medulla causes long-term decrease in blood pressure in the spontaneously hypertensive rats. Hypertension. 2007;49:926-931. (Pubitemid 351664196)
47. Feng Y, Xia H, Cai Y, et al. Brain-selective overexpression of human Angiotensin-converting enzyme type 2 attenuates neurogenic hypertension. Circ Res. 2010;106:373-382.
48. Thomas MC, Pickering RJ, Tsorotes D, et al. Genetic Ace2 deficiency accentuates vascular inflammation and atherosclerosis in the ApoE knockout mouse. Circ Res. 2010;107:888-897.
49. Zhang C, Zhao YX, Zhang YH, et al. Angiotensin-converting enzyme 2 attenuates atherosclerotic lesions by targeting vascular cells. Proc Natl Acad Sci USA. 2010;107:15886-15891.
50. Sampaio WO, Henrique Dde Castro C, Santos RA, et al. Angiotensin-(1-7) counterregulates angiotensin II signaling in human endothelial cells. Hypertension. 2007;50:1093-1098. (Pubitemid 350172931)
51. Sampaio WO, Souza dos Santos RA, Faria-Silva R, et al. Angiotensin-(1-7) through receptor Mas mediates endothelial nitric oxide synthase activation via Akt-dependent pathways. Hypertension. 2007;49:185-192. (Pubitemid 46360359)
52. Rabelo LA, Xu P, Todiras M, et al. Ablation of angiotensin (1-7) receptor Mas in C57Bl/6 mice causes endothelial dysfunction. J Am Soc Hypertens. 2008;2:418-424.
53. Xu P, Costa-Goncalves AC, Todiras M, et al. Endothelial dysfunction and elevated blood pressure in MAS gene-deleted mice. Hypertension. 2008;51:574-580. (Pubitemid 351156450)
54. Loot AE, Roks AJ, Henning RH, et al. Angiotensin-(1-7) attenuates the development of heart failure after myocardial infarction in rats. Circulation. 2002;105:1548-1550. (Pubitemid 34297630)
55. Benter IF, Yousif MH, Dhaunsi GS, et al. Angiotensin-(1-7) prevents activation of NADPH oxidase and renal vascular dysfunction in diabetic hypertensive rats. Am J Nephrol. 2008;28:25-33. (Pubitemid 350126490)
56. Benter IF, Yousif MH, Anim JT, et al. Angiotensin-(1-7) prevents development of severe hypertension and end-organ damage in spontaneously hypertensive rats treated with L-NAME. Am J Physiol Heart Circ Physiol. 2006;290:H684-H691.
57. Grobe JL, Mecca AP, Lingis M, et al. Prevention of angiotensin II-induced cardiac remodeling by angiotensin-(1-7). Am J Physiol Heart Circ Physiol. 2007;292:H736-H742.
58. Benter IF, Yousif MH, Cojocel C, et al. Angiotensin-(1-7) prevents diabetes-induced cardiovascular dysfunction. Am J Physiol Heart Circ Physiol. 2007;292:H666-H672. (Pubitemid 46105230)
59. Ebermann L, Spillmann F, Sidiropoulos M, et al. The angiotensin- (1-7) receptor agonist AVE0991 is cardioprotective in diabetic rats. Eur J Pharmacol. 2008;590:276-280.
60. Ferreira AJ, Oliveira TL, Castro MC, et al. Isoproterenol-induced impairment of heart function and remodeling are attenuated by the nonpeptide angiotensin-(1-7) analogue AVE 0991. Life Sci. 2007;81:916-923. (Pubitemid 47374211)
61. Ferreira AJ, Jacoby BA, Araujo CA, et al. The nonpeptide angiotensin-(1-7) receptor Mas agonist AVE-0991 attenuates heart failure induced by myocardial infarction. Am J Physiol Heart Circ Physiol. 2007;292:H1113- H1119.
62. Santos SH, Braga JF, Mario EG, et al. Improved lipid and glucose metabolism in transgenic rats with increased circulating angiotensin- (1-7). Arterioscler Thromb Vasc Biol. 2010;30:953-961.
63. Santos RA, Castro CH, Gava E, et al. Impairment of in vitro and in vivo heart function in angiotensin-(1-7) receptor MAS knockout mice. Hypertension. 2006;47:996-1002. (Pubitemid 44297574)
64. Dias-Peixoto MF, Santos RA, Gomes ER, et al. Molecular mechanisms involved in the angiotensin-(1-7)/Mas signaling pathway in cardiomyocytes. Hypertension. 2008;52:542-548.
65. Gomes ER, Lara AA, Almeida PW, et al. Angiotensin-(1-7) prevents cardiomyocyte pathological remodeling through a nitric oxide/guanosine 3′,5′-cyclic monophosphate-dependent pathway. Hypertension. 2010;55:153-1560.
66. Tallant EA, Ferrario CM, Gallagher PE. Angiotensin-(1-7) inhibits growth of cardiac myocytes through activation of the mas receptor. Am J Physiol Heart Circ Physiol. 2005;289:H1560-1566. (Pubitemid 41368998)
67. Urata H, Healy B, Stewart RW, et al. Angiotensin II-forming pathways in normal and failing human hearts. Circ Res. 1990;66:883-890. (Pubitemid 20126420)
68. Urata H, Kinoshita A, Misono KS, et al. Identification of a highly specific chymase as the major angiotensin II-forming enzyme in the human heart. J Biol Chem. 1990;265:22348-22357. (Pubitemid 120014308)
69. Jenne DE, Tschopp J. Angiotensin II-forming heart chymase is a mast-cell-specific enzyme. Biochem J. 1991;276:567-568.
70. Wei CC, Hase N, Inoue Y, et al. Mast cell chymase limits the cardiac efficacy of Ang I-converting enzyme inhibitor therapy in rodents. J Clin Invest. 2010;120:1229-1239.
71. Mackins CJ, Kano S, Seyedi N, et al. Cardiac mast cell-derived renin promotes local angiotensin formation, norepinephrine release, and arrhythmias in ischemia/reperfusion. J Clin Invest. 2006;116:1063-1070.
72. Hara M, Ono K, Hwang MW, et al. Evidence for a role of mast cells in the evolution to congestive heart failure. J Exp Med. 2002;195:375-381. (Pubitemid 34461496)
73. Juillerat L, Nussberger J, Menard J, et al. Determinants of angiotensin II generation during converting enzyme inhibition. Hypertension. 1990;16:564-572. (Pubitemid 20368346)
74. van de Wal RM, Plokker HW, Lok DJ, et al. Determinants of increased angiotensin II levels in severe chronic heart failure patients despite ACE inhibition. Int J Cardiol. 2006;106:367-372. (Pubitemid 41766640)
75. Roig E, Perez-Villa F, Morales M, et al. Clinical implications of increased plasma angiotensin II despite ACE inhibitor therapy in patients with congestive heart failure. Eur Heart J. 2000;21:53-57. (Pubitemid 30042669)
76. Ferrario CM, Jessup J, Chappell MC, et al. Effect of angiotensinconverting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation. 2005;111:2605-2610. (Pubitemid 40740859)
77. Ocaranza MP, Godoy I, Jalil JE, et al. Enalapril attenuates downregulation of Angiotensin-converting enzyme 2 in the late phase of ventricular dysfunction in myocardial infarcted rat. Hypertension. 2006;48:572-578. (Pubitemid 44843858)
78. Zhong JC, Ye JY, Jin HY, et al. Telmisartan attenuates aortic hypertrophy in hypertensive rats by the modulation of ACE2 and profilin-1 expression. Regul Pept. 2011;166:90-97.
79. Keidar S, Gamliel-Lazarovich A, Kaplan M, et al. Mineralocorticoid receptor blocker increases angiotensin-converting enzyme 2 activity in congestive heart failure patients. Circ Res. 2005;97:946-953. (Pubitemid 41552681)
80. Lambert DW, Yarski M, Warner FJ, et al. Tumor necrosis factoralpha convertase (ADAM17) mediates regulated ectodomain shedding of the severe-acute respiratory syndrome-coronavirus (SARS-CoV) receptor, angiotensin-converting enzyme-2 (ACE2). J Biol Chem. 2005;280:30113-3019.
81. Iwata M, Silva Enciso JE, Greenberg BH. elective and specific regulation of ectodomain shedding of angiotensin-converting enzyme 2 by tumor necrosis factor alpha-converting enzyme. Am J Physiol Cell Physiol. 2009;297:C1318-C1329.